Clinical trialsCompany release

Dianthus reports 75% CIDP response in claseprubart interim; MMN Phase 2 data due December

🇺🇸 Dianthus Therapeutics, Inc. /DE/ (DNTH) · Wed 04 Nov 2026

Dianthus Therapeutics' third-quarter update shows claseprubart beating its CIDP response target at interim, with MMN top-line results expected next month and cash guided into 2030.

Dianthus Therapeutics reported its third-quarter 2026 results on 4 November and gave an update on claseprubart, its lead candidate being developed in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN).

In CIDP, an interim analysis covered the first 40 participants in Part A of the Phase 3 CAPTIVATE study. The company said 75% of these participants responded, against a target response rate of 50%. The summary provided does not give further detail on the response definition or the full trial design.

For MMN, Dianthus expects to release top-line data from the Phase 2 MoMeNtum study in December 2026.

On finances, the company reported cash of about $1.2 billion, which it expects to fund operations into 2030.

What it means for your team

  • Regulatory teams tracking neuromuscular and autoimmune pipelines should note that the CIDP interim covers only 40 participants from Part A of a Phase 3 study, so it is not a final efficacy readout.
  • The December MMN top-line readout is the next datapoint to watch for claseprubart's potential in a third indication.
  • Market-access and competitive-intelligence teams can factor in the company's stated cash runway into 2030, which suggests development is funded well ahead of any filing decisions.

Company's press release (SEC filing): Dianthus Therapeutics, Inc. /DE/ ↗

Article written by VigiEye from the official source (Dianthus Therapeutics, Inc. /DE/). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →